Dupilumab for treating moderate to severe prurigo nodularis

Dupilumab (Dupixent, Sanofi) is indicated for 'the treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy'.

The dosage schedule is available in the summary of product characteristics for dupilumab.

The list price of dupilumab is £1,264.89 for a 2‑pack of 300 mg per 2 ml solution for injection prefilled syringes or pens (excluding VAT; BNF online accessed October 2023).

The company has a commercial arrangement. This makes dupilumab available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.